Welireg 40mg is manufactured by Merck Sharp and Dohme. We currently have this product available out of Switzerland.
Welireg is used to treat cancer of the kidneys and people with inherited Hippel-Lindau disease with cancer caused by that condition.
This product will non-English packaging from Europe. You will need to allow 2 weeks extra in order for us to bring in Welireg for sale.
Information about Welireg (Belzutifan)
Welireg (belzutifan) is a prescription medication used to treat certain types of kidney cancer. It is a hypoxia-inducible factor (HIF) inhibitor that works by blocking the activity of HIF-2α, a protein involved in the development of cancer. By inhibiting HIF-2α, Welireg helps slow the growth of cancer cells in patients with advanced renal cell carcinoma (RCC), particularly in cases associated with von Hippel-Lindau (VHL) disease, a genetic condition that increases the risk of developing kidney tumors.
Product Highlights
- It is used to treat adults with advanced clear cell renal cell carcinoma associated with von Hippel-Lindau disease who do not require immediate surgery.
- Welireg is specifically approved for treating kidney cancer in patients with VHL disease, a rare genetic disorder that predisposes individuals to tumors in various organs.
Key Ingredient
Key Benefits
- Belzutifan works by selectively inhibiting HIF-2α, helping to slow the growth of tumors, particularly in renal cell carcinoma associated with VHL disease.
- As an oral medication, it is easier for patients to manage compared to other cancer therapies that require intravenous infusions.
- Welireg has been shown to effectively reduce the size of tumors and slow disease progression in patients with advanced kidney cancer.
- It can be used for patients who do not require immediate surgical intervention for their tumors.
Direction of Use
- The recommended dose of Welireg for adults with advanced RCC associated with VHL disease is 120 mg, taken orally once daily.
- Welireg should be taken with or without food. It is typically taken as a whole tablet, and the dose should not be split, chewed, or crushed.
- It is important to take Welireg at the same time each day to help establish a routine. If you miss a dose, take it as soon as you remember, but skip it if it's nearly time for your next dose.
Safety Concerns
- One of the most common side effects of Welireg is anemia (low red blood cell count), which can lead to fatigue, dizziness, and weakness. Regular blood tests may be required to monitor for this.
- These are also common side effects, which may impact daily activities.
- In some patients, Welireg can cause elevated blood pressure. Blood pressure should be monitored regularly.
- Welireg may cause changes in liver enzymes, so liver function should be checked periodically.
- Welireg is not recommended during pregnancy, as it may harm the fetus. It is also unknown if it passes into breast milk, so breastfeeding should be avoided.
Avoid Welireg (Belzutifan) If
- You are pregnant or planning to become pregnant, as Welireg may harm the fetus.
- You are breastfeeding, as it is unknown if Welireg is excreted in human breast milk.
- You have severe liver disease, as Welireg may exacerbate liver function problems.
- You have a history of severe anemia or low red blood cell count, as Welireg can exacerbate this condition.
- You have uncontrolled high blood pressure or significant cardiovascular issues, as Welireg may increase blood pressure.
- You are allergic to belzutifan or any other ingredient in Welireg.
